Gallinamide A, originally isolated with a modest antimalarial activity, was subsequently
reisolated and characterized as a potent, selective, and irreversible inhibitor of the human …

Gallinamide A, a metabolite of the marine cyanobacterium Schizothrix sp., selectively
inhibits cathepsin L-like cysteine proteases. We evaluated the potency of gallinamide A and …

Trypanosoma cruzi and Trypanosoma brucei are parasites that cause Chagas' disease and
African sleeping sickness, respectively. Both parasites rely on essential cysteine proteases …

Chagas disease and human African trypanosomiasis are endemic conditions in Latin
America and Africa, respectively, for which no effective and safe therapy is available. Efforts …

Abstract Chagas disease, Human African Trypanosomiasis, and schistosomiasis are
neglected parasitic diseases for which new treatments are urgently needed. To identify new …

Papain‐like cysteine proteases of pathogenic protozoa play important roles in parasite
growth, differentiation and host cell invasion. The main cysteine proteases of Trypanosoma …

Trypanosoma cruzi, the causative agent of the American Trypanosomiasis, Chagas disease,
contains a major cysteine proteinase (CP), cruzipain (also known as cruzain, or GP57/51) …

The cysteine protease cruzipain is considered to be a validated target for therapeutic
intervention in the treatment of Chagas disease. Anti-trypanosomal activity against the CL …

Cruzain is the major cysteine protease of Trypanosoma cruzi, which is the causative agent of
Chagas disease and is a promising target for the development of new chemotherapy. With …

The cysteine proteases, cruzain and Tbr CATL (rhodesain), are therapeutic targets for
Chagas disease and Human African Trypanosomiasis, respectively. Among the known …